Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins
Journal of Chemical Theory and Computation · 10.11.2026 · 22 (21) · 11687-11704
DOI: 10.1021/acs.jctc.6c01007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Theory and Computation, online erschienen am 22.10.2026. Verfasst von Howook Hwang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Schrödinger, Inc. , 1540 Broadway, 24th Floor, New York, New York10036, United States. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Ether-A-Go-Go Potassium Channels, Receptors, Steroid, Small Molecule Libraries. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
The development of a small molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to as ADMET proteins, often contain large, highly flexible binding sites, leading to promiscuous binding of small molecules. This property often frustrates efforts to execute structure-based design against these anti-targets. Here, we demonstrate the application of a combination of induced fit docking and free energy perturbation to structurally enable several of the most common anti-targets: cytochrome P450 isoforms 3A4 and 2D6, the hERG ion channel, and PXR. Crucially, the enforcement of a consensus binding mode across a congeneric series allowed for the efficient exploration of a wide range of receptor conformational space. Results are presented for both public retrospective datasets and prospective application in active drug discovery programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Schrödinger, Inc. , 1540 Broadway, 24th Floor, New York, New York10036, United States.
- Schrödinger, Inc., 101 SW Main Street, Portland, Oregon97204, United States.
- Schrödinger, Inc. , 10201 Wateridge Circle, San Diego, California92121, United States.
- Nimbus Therapeutics , 22 Boston Wharf Rd, Boston, Massachusetts02210, United States.
- Pharmaron , West Hill Innovation Park, Hertford Rd, HoddesdonEN119FH, U.K.
- Department of Chemistry, Columbia University, 3000 Broadway, MC 3110, New York, New York10036, United States.
ORCID-Profile: Steven Albanese, Scott D Edmondson, Robert Pelletier, Richard A Friesner, Edward B Miller
Zitieren
APA
Hwang, H., Shelley, M., Placzek, A., DeMarco, K., Albanese, S., Verras, A., Kaila, N., McElwee, J., Campos, S., Caravella, J. A., Carreiro, S., Edmondson, S. D., Kreutter, K. D., Kumar, S., Toms, A. V., Tummino, P. J., Whitehead, L., So, S. S., Inoyama, D., …, & Miller, E. B. (2026). Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins. Journal of Chemical Theory and Computation, 22(21), 11687-11704. https://doi.org/10.1021/acs.jctc.6c01007
Vancouver
Hwang H, Shelley M, Placzek A, DeMarco K, Albanese S, Verras A, et al. Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins. Journal of Chemical Theory and Computation. 2026;22(21):11687-11704. doi:10.1021/acs.jctc.6c01007
BibTeX
@article{Hwang2026,
author = {Hwang, Howook and Shelley, Mee and Placzek, Andrew and DeMarco, Kevin and Albanese, Steven and Verras, Andreas and Kaila, Neelu and McElwee, Joshua and Campos, Sebastien and Caravella, Justin A and Carreiro, Samantha and Edmondson, Scott D and Kreutter, Kevin D and Kumar, Sheetal and Toms, Angela V and Tummino, Peter J and Whitehead, Lewis and So, Sung-Sau and Inoyama, Daigo and Konze, Kyle and Pelletier, Robert and Xu, Tianchuan and Abel, Robert and Friesner, Richard A and Miller, Edward B},
title = {Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins},
journal = {Journal of Chemical Theory and Computation},
year = {2026},
volume = {22},
number = {21},
pages = {11687--11704},
doi = {10.1021/acs.jctc.6c01007}
}
EUVIMED